NervGen Pharma Corp. (NGENF)
NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
📈 **POSITIVE** • High confidence analysis (94%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical